Penn Cardiovascular Institute

Penn Cardiovascular Institute Research Directory

faculty photo

Vladimir R. Muzykantov, MD, PhD

Professor of Pharmacology
Department: Pharmacology
Graduate Group Affiliations

Contact information
10-125 Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104-5158
Office: 215-898-9823
Fax: 215-898-0868
Education:
M.D. (Internal Medicine)
First School of Medicine, Moscow, Russia, 1980.
Ph.D. (Biochemistry)
National Cardiology Research Center, Moscow, Russia, 1985.
M.A. (Honoris Causa)
University of Pennsylvania, 2004.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of CVI Expertise

CVI Program Unit(s):
Biotechnology / Nanomedicine / Imaging
Thrombosis / Hemostasis

CVI Research Description:
Dr. Muzykantov focuses on targeted drug delivery to the endothelium and blood cells for treatment of thrombosis, ischemia and other cardiovascular maladies. He also teaches cardiovascular biology to graduate students in pharmacology.

Selected Publications

Liu Jin, Weller Gregory E R, Zern Blaine, Ayyaswamy Portonovo S, Eckmann David M, Muzykantov Vladimir R, Radhakrishnan Ravi: Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proceedings of the National Academy of Sciences of the United States of America 107(38): 16530-5, Sep 2010.

Muzykantov Vladimir R: NO gets a test ride on high-tech transporting nanodevices: A commentary on "Sustained-release nitric oxide from long-lived circulating nanoparticles". Free radical biology & medicine 49(4): 528-9, Aug 2010.

Chorny Michael, Hood Elizabeth, Levy Robert J, Muzykantov Vladimir R: Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J. Controlled Release 146(1): 144-51, Aug 2010.

Zaitsev Sergei, Spitzer Dirk, Murciano Juan-Carlos, Ding Bi-Sen, Tliba Samira, Kowalska M Anna, Marcos-Contreras Oscar A, Kuo Alice, Stepanova Victoria, Atkinson John P, Poncz Mortimer, Cines Douglas B, Muzykantov Vladimir R: Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 115(25): 5241-8, Jun 2010.

Armstead William M, Ganguly Kumkum, Kiessling J W, Riley John, Chen Xiao-Han, Smith Douglas H, Stein Sherman C, Higazi Abd A R, Cines Douglas B, Bdeir Khalil, Zaitsev Sergei, Muzykantov Vladimir R: Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. Journal of neurochemistry 113(2): 303-12, Apr 2010.

Muzykantov Vladimir R: Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert opinion on drug delivery 7(4): 403-27, Apr 2010.

Zaitsev Sergei, Zaitzev Sergei, Spitzer Dirk, Murciano Juan-Carlos, Ding Bi-Sen, Tliba Samira, Kowalska M Anna, Bdeir Khalil, Kuo Alice, Stepanova Victoria, Atkinson John P, Poncz Mortimer, Cines Douglas B, Muzykantov Vladimir R: Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. The Journal of pharmacology and experimental therapeutics 332(3): 1022-31, Mar 2010.

Shuvaev Vladimir V, Christofidou-Solomidou Melpo, Bhora Faiz, Laude Karine, Cai Hua, Dikalov Sergei, Arguiri Evguenia, Solomides Charalambos C, Albelda Steven M, Harrison David G, Muzykantov Vladimir R: Targeted detoxification of selected reactive oxygen species in the vascular endothelium. The Journal of pharmacology and experimental therapeutics 331(2): 404-11, Nov 2009.

Murciano Juan-Carlos, Higazi Abd Al-Roof, Cines Douglas B, Muzykantov Vladimir R: Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Controlled Release 139(3): 190-6, Nov 2009.

Stein Sherman C, Ganguly Kumkum, Belfield Caitlin M, Xu Xiangsheng, Swanson Edward W, Chen Xiao-Han, Browne Kevin D, Johnson Victoria E, Smith Douglas H, LeBold David G, Cines Douglas B, Muzykantov Vladimir R, Muzykhantov Vladimir R: Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. Journal of neurotrauma 26(9): 1585-92, Sep 2009.

back to top
Last updated: 09/11/2012
The Trustees of the University of Pennsylvania